CytomX Therapeutics (CTMX)
Market Price (2/4/2026): $6.06 | Market Cap: $999.9 MilSector: Health Care | Industry: Biotechnology
CytomX Therapeutics (CTMX)
Market Price (2/4/2026): $6.06Market Cap: $999.9 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -14% | Trading close to highsDist 52W High is -0.3%, Dist 3Y High is -0.3% | Expensive valuation multiplesP/EBITPrice/EBIT or Price/(Operating Income) ratio is 43x, P/EPrice/Earnings or Price/(Net Income) is 36x |
| Attractive operating marginsOp Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 20% | Stock price has recently run up significantly6M Rtn6 month market price return is 156%, 12M Rtn12 month market price return is 623% | |
| Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, Biopharmaceutical R&D, Show more. | Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -10%, Rev Chg QQuarterly Revenue Change % is -82% | |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -64%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -64% | ||
| Valuation getting more expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 202% | ||
| High stock price volatilityVol 12M is 162% | ||
| Key risksCTMX key risks include [1] a heavy dependence on its unproven PROBODY® therapeutic technology platform, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -14% |
| Attractive operating marginsOp Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 20% |
| Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, Biopharmaceutical R&D, Show more. |
| Trading close to highsDist 52W High is -0.3%, Dist 3Y High is -0.3% |
| Expensive valuation multiplesP/EBITPrice/EBIT or Price/(Operating Income) ratio is 43x, P/EPrice/Earnings or Price/(Net Income) is 36x |
| Stock price has recently run up significantly6M Rtn6 month market price return is 156%, 12M Rtn12 month market price return is 623% |
| Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -10%, Rev Chg QQuarterly Revenue Change % is -82% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -64%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -64% |
| Valuation getting more expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 202% |
| High stock price volatilityVol 12M is 162% |
| Key risksCTMX key risks include [1] a heavy dependence on its unproven PROBODY® therapeutic technology platform, Show more. |
Qualitative Assessment
AI Analysis | Feedback
1. Continued positive clinical development and anticipation of key data for CX-2051 in colorectal cancer.CytomX Therapeutics generated sustained investor interest through ongoing positive updates and upcoming milestones for its lead asset, CX-2051. Earlier in 2025, positive interim data from its Phase 1 study in advanced colorectal cancer (CRC) laid a strong foundation. During the analysis period, the company consistently guided for a significant Phase 1 data update for CX-2051 in Q1 2026, which was highly anticipated by the market. Plans to initiate a Phase 2 study in the first half of 2026 and discussions with the FDA in 2026 regarding a potential registrational monotherapy study further boosted confidence in the drug's path forward.
2. Enhanced financial stability and extended cash runway.The company demonstrated improved financial health, which de-risked the investment for shareholders. CytomX's strategic decision in early 2025 to streamline operations, including a significant headcount reduction, resulted in cost savings and an extension of its cash runway into the second quarter of 2026. By Q2 2025, the cash runway was further extended into Q2 2027 with $158.1 million in cash, signaling stronger liquidity and reduced immediate funding concerns.
Show more
Stock Movement Drivers
Fundamental Drivers
The 70.0% change in CTMX stock from 10/31/2025 to 2/3/2026 was primarily driven by a 272.2% change in the company's P/E Multiple.| (LTM values as of) | 10312025 | 2032026 | Change |
|---|---|---|---|
| Stock Price ($) | 3.57 | 6.07 | 70.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 141 | 114 | -19.5% |
| Net Income Margin (%) | 34.0% | 24.7% | -27.5% |
| P/E Multiple | 9.6 | 35.7 | 272.2% |
| Shares Outstanding (Mil) | 129 | 165 | -21.8% |
| Cumulative Contribution | 70.0% |
Market Drivers
10/31/2025 to 2/3/2026| Return | Correlation | |
|---|---|---|
| CTMX | 70.0% | |
| Market (SPY) | 1.1% | 20.6% |
| Sector (XLV) | 6.8% | 4.4% |
Fundamental Drivers
The 177.2% change in CTMX stock from 7/31/2025 to 2/3/2026 was primarily driven by a 679.5% change in the company's P/E Multiple.| (LTM values as of) | 7312025 | 2032026 | Change |
|---|---|---|---|
| Stock Price ($) | 2.19 | 6.07 | 177.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 148 | 114 | -23.0% |
| Net Income Margin (%) | 28.2% | 24.7% | -12.5% |
| P/E Multiple | 4.6 | 35.7 | 679.5% |
| Shares Outstanding (Mil) | 87 | 165 | -47.2% |
| Cumulative Contribution | 177.2% |
Market Drivers
7/31/2025 to 2/3/2026| Return | Correlation | |
|---|---|---|
| CTMX | 177.2% | |
| Market (SPY) | 9.4% | 9.1% |
| Sector (XLV) | 18.7% | 7.3% |
Fundamental Drivers
The 614.1% change in CTMX stock from 1/31/2025 to 2/3/2026 was primarily driven by a 583.5% change in the company's P/E Multiple.| (LTM values as of) | 1312025 | 2032026 | Change |
|---|---|---|---|
| Stock Price ($) | 0.85 | 6.07 | 614.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 127 | 114 | -10.3% |
| Net Income Margin (%) | 10.9% | 24.7% | 125.7% |
| P/E Multiple | 5.2 | 35.7 | 583.5% |
| Shares Outstanding (Mil) | 85 | 165 | -48.4% |
| Cumulative Contribution | 614.1% |
Market Drivers
1/31/2025 to 2/3/2026| Return | Correlation | |
|---|---|---|
| CTMX | 614.1% | |
| Market (SPY) | 15.6% | 25.5% |
| Sector (XLV) | 6.3% | 20.8% |
Fundamental Drivers
The 124.8% change in CTMX stock from 1/31/2023 to 2/3/2026 was primarily driven by a 454.1% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 1312023 | 2032026 | Change |
|---|---|---|---|
| Stock Price ($) | 2.70 | 6.07 | 124.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 21 | 114 | 454.1% |
| P/S Multiple | 8.7 | 8.8 | 1.6% |
| Shares Outstanding (Mil) | 66 | 165 | -60.1% |
| Cumulative Contribution | 124.8% |
Market Drivers
1/31/2023 to 2/3/2026| Return | Correlation | |
|---|---|---|
| CTMX | 124.8% | |
| Market (SPY) | 75.9% | 14.4% |
| Sector (XLV) | 20.9% | 15.0% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| CTMX Return | -34% | -63% | -3% | -34% | 314% | 43% | -7% |
| Peers Return | -35% | -61% | -33% | -45% | -4% | -5% | -91% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 2% | 86% |
Monthly Win Rates [3] | |||||||
| CTMX Win Rate | 42% | 33% | 58% | 33% | 42% | 100% | |
| Peers Win Rate | 31% | 35% | 35% | 40% | 50% | 62% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 100% | |
Max Drawdowns [4] | |||||||
| CTMX Max Drawdown | -41% | -73% | -33% | -44% | -58% | -4% | |
| Peers Max Drawdown | -37% | -85% | -70% | -51% | -60% | -19% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -1% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: ADCT, BCAB, MGNX, STRO.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 2/3/2026 (YTD)
How Low Can It Go
| Event | CTMX | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -89.2% | -25.4% |
| % Gain to Breakeven | 826.2% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -58.0% | -33.9% |
| % Gain to Breakeven | 138.1% | 51.3% |
| Time to Breakeven | 28 days | 148 days |
| 2018 Correction | ||
| % Loss | -84.9% | -19.8% |
| % Gain to Breakeven | 561.9% | 24.7% |
| Time to Breakeven | Not Fully Recovered days | 120 days |
Compare to ADCT, BCAB, MGNX, STRO
In The Past
CytomX Therapeutics's stock fell -89.2% during the 2022 Inflation Shock from a high on 4/28/2021. A -89.2% loss requires a 826.2% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About CytomX Therapeutics (CTMX)
AI Analysis | Feedback
Here are 1-3 brief analogies for CytomX Therapeutics (CTMX):
- "Genentech for precision-activated cancer drugs."
- "Moderna for targeted antibody cancer therapies."
- "An early-stage Amgen, focused on developing smarter, safer antibody drugs for cancer."
AI Analysis | Feedback
- Probody™ Platform Technology: A proprietary drug discovery platform designed to create tumor-activated therapeutics that remain masked and inactive in healthy tissue, thus reducing systemic toxicity.
- CX-904: A T-cell activating bispecific antibody designed to target EGFR and CD3, currently in clinical development in collaboration with Bristol Myers Squibb for solid tumors.
- CX-801: A Probody™ cytokine therapeutic targeting Interferon Alpha-2b, in clinical development as a wholly-owned asset for the treatment of solid tumors.
- CX-2029: A Probody™ antibody-drug conjugate (ADC) designed to target CD71, in clinical development as a wholly-owned asset for the treatment of various cancers.
AI Analysis | Feedback
CytomX Therapeutics (CTMX) Major Customers
CytomX Therapeutics is a clinical-stage biotechnology company that develops novel cancer therapies. As such, it sells primarily to other companies, specifically larger pharmaceutical and biotechnology companies through collaboration, licensing, and research agreements, rather than directly to individuals.
Based on their financial filings and public disclosures, their major customer providing significant revenue from ongoing collaborations is:
- Bristol Myers Squibb Company (BMS)
CytomX Therapeutics has historically engaged in other collaborations with companies like Amgen and AbbVie, but the agreement with Bristol Myers Squibb has been a consistent and significant source of collaboration revenue in recent years, as detailed in their annual reports (10-K filings).
AI Analysis | Feedback
- AGC Biologics (TYO: 5201)
- Lonza (SWX: LONN)
- WuXi Biologics (HKEX: 2269)
- Catalent Pharma Solutions (NYSE: CTLT)
AI Analysis | Feedback
Sean A. McCarthy, D.Phil. Chief Executive Officer and Chairman
Dr. McCarthy joined CytomX in December 2010 as Chief Business Officer and became President and CEO in August 2011. He was appointed Chairman of the board in January 2019. With over twenty-five years of experience in the biotechnology industry, his background encompasses roles in R&D, business development, financing, and general management. Prior to joining CytomX, Dr. McCarthy was a transactional partner at Pappas Ventures from April 2006 to December 2010, focusing on investments in therapeutic, medical device, and molecular diagnostic companies.
Chris Ogden Chief Financial Officer
Mr. Ogden joined CytomX in August 2021. He brings 16 years of experience from Eli Lilly and Company, where he held various senior financial leadership positions, including Chief Financial Officer of Lilly Diabetes. He also served as Chief Financial Officer and Treasurer of Lilly del Caribe in Puerto Rico, and held financial leadership roles in drug development, manufacturing, commercial operations, and investor relations.
Wayne Chu, M.D. Chief Medical Officer
Dr. Chu joined CytomX as Chief Medical Officer in July 2023. He has more than 20 years of experience in oncology, spanning research, medicine, and global clinical development. Before CytomX, Dr. Chu served as Chief Medical Officer at Fate Therapeutics, overseeing clinical development strategies for novel immune cell therapies. He previously spent a decade at Genentech in Product Development Oncology, where he was involved in the development of therapies such as trastuzumab emtansine (Kadcyla), polatuzumab vedotin, tiragolumab, and mosunetuzumab. His clinical training was in pediatric hematology-oncology at Johns Hopkins School of Medicine and the National Cancer Institute.
Marcia P. Belvin, Ph.D. SVP, Chief Scientific Officer
Dr. Belvin joined CytomX in 2018 and has nearly 20 years of industry experience in oncology research and drug discovery. Prior to CytomX, she spent over 13 years at Genentech, where she held roles of increasing responsibility, leading multiple preclinical pipeline teams and overseeing programs in cancer signaling, cancer metabolism, and cancer immunology. She began her career at Exelixis, managing teams responsible for preclinical pipeline discovery within oncology and inflammation portfolios.
Leslie Robbins, J.D. SVP, Intellectual Property
Ms. Robbins joined CytomX in February 2019, bringing more than 25 years of legal experience in the biotechnology industry. Most recently, she was the Vice President of Intellectual Property at Coherus BioSciences. Her prior experience includes intellectual property roles at Onyx Pharmaceuticals (which was acquired by Amgen) and Elan Pharmaceuticals. She began her legal career at a boutique patent firm and was a research associate at Chiron Corporation before law school.
AI Analysis | Feedback
CytomX Therapeutics (CTMX) faces several key risks inherent to the biotechnology industry, primarily centered on the success of its drug development pipeline and its financial sustainability.- Clinical Development and Regulatory Approval Risk: As a clinical-stage biopharmaceutical company, CytomX Therapeutics' business success is heavily dependent on the successful development, clinical trial outcomes, and eventual regulatory approval of its product candidates, such as CX-2051 and CX-801. Any setbacks, including negative clinical trial results, delays in trials, or difficulties in securing regulatory approvals, could significantly harm the company's operations and financial standing. The company's proprietary PROBODY® therapeutic technology remains unproven until a drug reaches commercialization. Past program terminations with partners like Amgen and AbbVie highlight the speculative nature of drug development. Upcoming data readouts for CX-2051 in Q1 2026 present a significant catalyst, where disappointing results could lead to a decline in stock value. Additionally, potential toxicity issues for CX-2051 have been noted.
- Financial and Funding Risk: CytomX Therapeutics' revenue is primarily derived from collaboration agreements, which are inherently volatile and can fluctuate based on milestone payments and program activities. The company experienced a substantial decline in collaboration revenue in 2025 due to the completion of obligations with Bristol Myers Squibb and reduced activity with Moderna. While CytomX projects its cash reserves to fund operations until Q2 2027, it consistently operates at a net loss and burns cash for research and development activities. This financial model necessitates future fundraising, potentially through equity offerings, which could result in the dilution of existing shareholders.
- Competition Risk: The biotechnology and biopharmaceutical sectors are characterized by rapid technological advancements, intense competition, and robust intellectual property defense. CytomX's investigational therapies must compete with established treatments and new drugs that may emerge in the future. Strong data reported by competitors in similar therapeutic areas or indications could also diminish the potential impact of positive results from CytomX's clinical trials.
AI Analysis | Feedback
The continuous and rapid advancement of alternative drug modalities in oncology, particularly next-generation Antibody-Drug Conjugates (ADCs) and bispecific T-cell engagers (TCEs), that achieve comparable or superior efficacy and safety profiles without requiring conditional activation. As competitors innovate with novel payloads, linkers, and engineering formats, they are increasingly able to deliver potent agents selectively to tumors with reduced systemic toxicity, thereby potentially diminishing the unique value proposition and market need for CytomX's Probody platform.
AI Analysis | Feedback
CytomX Therapeutics (CTMX) is a clinical-stage biopharmaceutical company focused on developing novel conditionally activated, masked biologics for cancer treatment. Its main clinical-stage products are CX-2051, CX-801, and CX-904.
Main Products and Addressable Markets:
- CX-2051 (EpCAM PROBODY Topo-1 ADC): This antibody-drug conjugate targets epithelial cell adhesion molecule (EpCAM) and is being developed for EpCAM-expressing epithelial cancers, with a primary focus on advanced metastatic colorectal cancer (CRC).
- Colorectal Cancer Therapeutics Market: The global colorectal cancer therapeutics market was valued at USD 18.5 billion in 2023 and is projected to reach USD 30.7 billion by 2030, growing at a CAGR of 7.5% from 2024 to 2030. The U.S. market for colorectal cancer therapeutics was estimated at USD 6.5 billion in 2023.
- CX-801 (PROBODY Interferon alpha-2b): This masked interferon alpha-2b cytokine has broad potential in both immuno-oncology sensitive and insensitive (cold) tumors. It is currently in a Phase 1 study focusing on advanced melanoma, both as a monotherapy and in combination with pembrolizumab (KEYTRUDA®).
- Melanoma Therapeutics Market: The global melanoma therapeutics market size was valued at USD 11.2 billion in 2023 and is projected to reach USD 26.5 billion by 2033, growing at a CAGR of 9.2% during the forecast period. North America held the largest share of this market.
- CX-904 (EGFRxCD3 T-cell engager): This T-cell engaging bispecific antibody targets the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells. It is partnered with Amgen and is in a Phase 1 study for advanced solid tumors.
- EGFR-Positive Solid Tumors Market: Given the broad targeting of solid tumors with EGFR expression, the addressable market encompasses various cancers.
- Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market: The global non-small cell lung cancer therapeutics market was estimated at USD 20.2 billion in 2024 and is expected to grow to USD 53.9 billion by 2034, at a CAGR of 10.4% from 2025 to 2034. The market across the top 7 markets (U.S., EU4, U.K., and Japan) reached USD 12.2 billion in 2024 and is expected to reach USD 25.0 billion by 2035. The U.S. non-small cell lung cancer market was valued at USD 8.2 billion in 2024.
- Breast Cancer Therapeutics Market: The global breast cancer market size was valued at USD 35.22 billion in 2023 and is poised to grow from USD 38.89 billion in 2024 to USD 86 billion by 2032, at a CAGR of 10.43% during the forecast period (2025-2032). The U.S. breast cancer market size was estimated at USD 7.71 billion in 2024 and is expected to reach approximately USD 11.55 billion by 2034.
- Colorectal Cancer Therapeutics Market: As mentioned for CX-2051, the global colorectal cancer therapeutics market was valued at USD 18.5 billion in 2023 and is projected to reach USD 30.7 billion by 2030, growing at a CAGR of 7.5% from 2024 to 2030.
- EGFR-Positive Solid Tumors Market: Given the broad targeting of solid tumors with EGFR expression, the addressable market encompasses various cancers.
AI Analysis | Feedback
CytomX Therapeutics (CTMX) has several key drivers anticipated to fuel future revenue growth over the next 2-3 years, primarily centered around its proprietary Probody platform and advancing clinical pipeline:
-
Advancement and Potential Commercialization of CX-2051: CytomX's lead wholly-owned program, CX-2051, an EpCAM PROBODY ADC, is a significant driver. The company expects a Phase 1 data update in Q1 2026 for its ongoing expansion study in advanced metastatic colorectal cancer (CRC), with projected enrollment of approximately 100 patients. Furthermore, a Phase 1b combination study of CX-2051 with bevacizumab in CRC is slated to begin in Q1 2026. Successful progression through these clinical milestones and towards a potential registrational study in advanced, late-line CRC, along with evaluation for other EpCAM-expressing indications, could lead to substantial revenue generation from this "first-in-class" candidate.
-
Clinical Progress and Partnership Success with CX-801: The PROBODY Interferon alpha-2b program, CX-801, is advancing, particularly in combination with KEYTRUDA for metastatic melanoma. A Phase 1 dose escalation study is ongoing, and initial data for the CX-801-KEYTRUDA combination is anticipated by the end of 2026. Positive data and continued development could trigger milestone payments from partners and pave the way for future product revenue as this molecule aims to stimulate an anti-tumor immune response.
-
New and Ongoing Strategic Collaborations and Milestone Payments: CytomX maintains strategic collaborations with pharmaceutical giants such as Bristol Myers Squibb, Astellas, Regeneron, and Moderna. While some performance obligations with existing partners have been completed, the company continues to focus on T-cell engager discovery work and expects potential milestone payments from these and new collaborations over the next 1-2 years. These collaborations provide non-dilutive capital and validate CytomX's proprietary Probody technology, contributing to revenue streams.
AI Analysis | Feedback
Share Issuance
- In May 2025, CytomX Therapeutics announced the pricing of an underwritten public offering of 76,923,076 shares of common stock at $1.30 per share, aiming to raise approximately $100 million in gross proceeds.
- The company completed an underwritten public offering in January 2021, selling 14,285,714 shares of common stock at $7.00 per share, generating gross proceeds of $100 million.
- In February 2021, the underwriters of the January 2021 offering fully exercised their option to purchase an additional 2,142,857 shares of common stock, resulting in net proceeds of approximately $107.7 million from the entire offering.
Inbound Investments
- In January 2023, CytomX entered a strategic collaboration and licensing agreement with Moderna for mRNA-based conditionally activated therapies, which included an upfront payment of $35 million (including $5 million in prepaid research funding) to CytomX.
- In November 2022, CytomX announced a collaboration and licensing agreement with Regeneron to develop conditionally-activated bispecific cancer therapies, under which Regeneron paid an upfront payment of $30 million to CytomX.
- In June 2023, CytomX entered into a private placement agreement with BVF Partners L.P., expected to result in initial gross proceeds of approximately $30 million, with the potential to receive up to an additional $60 million if all warrants are fully exercised for cash.
Capital Expenditures
- For the 12 months ending November 4, 2025, CytomX Therapeutics reported capital expenditures of -$245,000.
- CytomX expects to use net proceeds from its offerings, including the January 2021 offering, for capital expenditures, working capital, and other general corporate purposes.
- The company's property, plant & equipment value as of June 30, 2025, was $7.89 million, compared to $10.6 million at the end of 2024 and $16.18 million at the end of 2023, indicating a decrease in fixed asset base.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| CytomX Therapeutics Earnings Notes | 12/16/2025 | |
| Can CytomX Therapeutics Stock Hold Up When Markets Turn? | 10/17/2025 | |
| Day 6 of Gains Streak for CytomX Therapeutics Stock with 63% Return (vs. 214% YTD) [9/29/2025] | 09/30/2025 |
| Title | |
|---|---|
| ARTICLES |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 3.90 |
| Mkt Cap | 0.1 |
| Rev LTM | 106 |
| Op Inc LTM | -114 |
| FCF LTM | -132 |
| FCF 3Y Avg | -83 |
| CFO LTM | -132 |
| CFO 3Y Avg | -80 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | -10.3% |
| Rev Chg 3Y Avg | 34.2% |
| Rev Chg Q | -34.2% |
| QoQ Delta Rev Chg LTM | -19.5% |
| Op Mgn LTM | -109.7% |
| Op Mgn 3Y Avg | -120.4% |
| QoQ Delta Op Mgn LTM | -4.0% |
| CFO/Rev LTM | -152.2% |
| CFO/Rev 3Y Avg | -111.2% |
| FCF/Rev LTM | -153.3% |
| FCF/Rev 3Y Avg | -112.9% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 0.1 |
| P/S | 4.1 |
| P/EBIT | -0.7 |
| P/E | -0.6 |
| P/CFO | -0.7 |
| Total Yield | -68.6% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | -65.8% |
| D/E | 0.2 |
| Net D/E | -0.2 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 10.8% |
| 3M Rtn | 20.7% |
| 6M Rtn | 41.3% |
| 12M Rtn | -21.9% |
| 3Y Rtn | -68.7% |
| 1M Excs Rtn | 9.9% |
| 3M Excs Rtn | 4.3% |
| 6M Excs Rtn | 33.6% |
| 12M Excs Rtn | -37.3% |
| 3Y Excs Rtn | -139.5% |
Price Behavior
| Market Price | $6.07 | |
| Market Cap ($ Bil) | 1.0 | |
| First Trading Date | 10/08/2015 | |
| Distance from 52W High | -0.3% | |
| 50 Days | 200 Days | |
| DMA Price | $4.50 | $2.95 |
| DMA Trend | up | up |
| Distance from DMA | 35.0% | 106.0% |
| 3M | 1YR | |
| Volatility | 92.4% | 162.2% |
| Downside Capture | -41.94 | 13.32 |
| Upside Capture | 190.72 | 214.84 |
| Correlation (SPY) | 20.4% | 25.6% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | -0.20 | 0.14 | 1.62 | 0.93 | 2.14 | 1.59 |
| Up Beta | 0.09 | 0.62 | 5.06 | 2.89 | 3.47 | 2.52 |
| Down Beta | 2.11 | 1.22 | 1.82 | 1.66 | 1.36 | 1.89 |
| Up Capture | 153% | 111% | 232% | 138% | 415% | 93% |
| Bmk +ve Days | 11 | 22 | 34 | 71 | 142 | 430 |
| Stock +ve Days | 7 | 19 | 33 | 63 | 126 | 327 |
| Down Capture | -654% | -254% | -78% | -196% | 31% | 96% |
| Bmk -ve Days | 9 | 19 | 27 | 54 | 109 | 321 |
| Stock -ve Days | 13 | 22 | 28 | 62 | 124 | 379 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with CTMX | |
|---|---|---|---|---|
| CTMX | 653.3% | 162.1% | 1.80 | - |
| Sector ETF (XLV) | 6.3% | 17.2% | 0.20 | 20.6% |
| Equity (SPY) | 15.6% | 19.2% | 0.63 | 25.4% |
| Gold (GLD) | 77.2% | 24.5% | 2.30 | -1.4% |
| Commodities (DBC) | 10.0% | 16.5% | 0.40 | 9.4% |
| Real Estate (VNQ) | 2.9% | 16.5% | -0.00 | 9.1% |
| Bitcoin (BTCUSD) | -23.4% | 40.3% | -0.56 | 3.3% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with CTMX | |
|---|---|---|---|---|
| CTMX | -1.8% | 140.1% | 0.43 | - |
| Sector ETF (XLV) | 7.8% | 14.4% | 0.36 | 16.3% |
| Equity (SPY) | 14.5% | 17.0% | 0.68 | 16.2% |
| Gold (GLD) | 21.5% | 16.8% | 1.04 | 3.6% |
| Commodities (DBC) | 12.0% | 18.9% | 0.51 | -1.3% |
| Real Estate (VNQ) | 4.8% | 18.8% | 0.16 | 11.3% |
| Bitcoin (BTCUSD) | 20.9% | 57.5% | 0.56 | 3.7% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with CTMX | |
|---|---|---|---|---|
| CTMX | -9.0% | 110.0% | 0.30 | - |
| Sector ETF (XLV) | 10.4% | 16.6% | 0.52 | 22.8% |
| Equity (SPY) | 15.6% | 17.9% | 0.75 | 22.5% |
| Gold (GLD) | 15.6% | 15.5% | 0.84 | 3.1% |
| Commodities (DBC) | 8.4% | 17.6% | 0.39 | 3.2% |
| Real Estate (VNQ) | 5.6% | 20.8% | 0.24 | 15.7% |
| Bitcoin (BTCUSD) | 69.9% | 66.5% | 1.09 | 6.0% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 11/6/2025 | -13.6% | -7.9% | -7.2% |
| 8/7/2025 | 11.9% | -16.2% | 3.8% |
| 3/6/2025 | 7.7% | -4.3% | -26.2% |
| 11/7/2024 | 9.0% | 0.0% | 26.0% |
| 8/8/2024 | 1.7% | 0.8% | 5.9% |
| 3/11/2024 | -14.3% | -19.5% | -16.3% |
| 11/7/2023 | -2.3% | 0.0% | 14.1% |
| 8/8/2023 | -3.6% | -5.9% | -18.3% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 11 | 8 | 6 |
| # Negative | 9 | 12 | 14 |
| Median Positive | 7.7% | 1.5% | 10.0% |
| Median Negative | -6.1% | -7.6% | -12.7% |
| Max Positive | 16.2% | 17.2% | 31.7% |
| Max Negative | -15.1% | -24.7% | -31.7% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 09/30/2025 | 11/06/2025 | 10-Q |
| 06/30/2025 | 08/07/2025 | 10-Q |
| 03/31/2025 | 05/12/2025 | 10-Q |
| 12/31/2024 | 03/06/2025 | 10-K |
| 09/30/2024 | 11/07/2024 | 10-Q |
| 06/30/2024 | 08/08/2024 | 10-Q |
| 03/31/2024 | 05/08/2024 | 10-Q |
| 12/31/2023 | 03/11/2024 | 10-K |
| 09/30/2023 | 11/07/2023 | 10-Q |
| 06/30/2023 | 08/08/2023 | 10-Q |
| 03/31/2023 | 05/09/2023 | 10-Q |
| 12/31/2022 | 03/27/2023 | 10-K |
| 09/30/2022 | 11/08/2022 | 10-Q |
| 06/30/2022 | 08/04/2022 | 10-Q |
| 03/31/2022 | 05/05/2022 | 10-Q |
| 12/31/2021 | 03/01/2022 | 10-K |
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | McCarthy, Sean A | CEO | Direct | Sell | 11102025 | 4.54 | 101,793 | 461,906 | 4,482,753 | Form |
| 2 | Ogden, Christopher | Chief Financial Officer | Direct | Sell | 6172025 | 2.95 | 1,641 | 4,841 | 588,246 | Form |
| 3 | Ogden, Christopher | Chief Financial Officer | Direct | Sell | 6172025 | 2.69 | 10,614 | 28,540 | 608,420 | Form |
| 4 | Belvin, Marcia | SVP, Chief Scientific Officer | Direct | Sell | 6172025 | 2.69 | 13,884 | 37,334 | 732,086 | Form |
| 5 | McCarthy, Sean A | CEO | Direct | Sell | 6172025 | 2.69 | 55,511 | 149,264 | 2,930,051 | Form |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.